Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over a quarter of the world's population. To halt its progression from simple fatty liver to irreversible liver cancer, the attention of the scientists has turned to the "gut-liver nexus," which is the biological highway connecting our digestive tract to our metabolic engine.

In a study published in Cell Press Blue on May 27, a team led by Prof. TAN Zhiliang from the Institute of Subtropical Agriculture of the Chinese Academy of Sciences, along with international collaborators, provided a comprehensive blueprint for harnessing the gut bacterium Akkermansia muciniphila (AKK) as a next-generation probiotic to treat chronic liver diseases.

"We have discovered how AKK acts as a microscopic bricklayer in the gut. It has been demonstrated that AKK strengthens the intestinal mucosal barrier by stimulating Mucin 2 synthesis in goblet cells, effectively blocking toxic endotoxins (LPS) from escaping the gut," said Prof. TAN.

In this study, based on global clinical data, the researchers mapped out how this single bacterium exerts multi-dimensional, systemic protection across the entire spectrum of fatty liver disease through four core pathways: plugging the "leaky gut," calming the liver's immune storm, rewiring metabolic networks, and paving the way for precision medicine.

AKK secretes specific key proteins that tighten cellular junctions and prompt gut stem cells to renew the protective mucus layer, cutting off the leakage of inflammatory molecules into the bloodstream. Once AKK-derived vesicles travel through the portal vein to the liver, they coax the liver's resident immune cells into a healing "M2" state, dampening chronic inflammation and preventing tissue scarring.

Through a process of "microbial teamwork," AKK reshapes the gut's bile acid profile. This chemical signal travels to the liver, turning off genes that produce fat, while switching on genes that burn fat, relieving liver lipid toxicity. The clinical efficacy of AKK depends heavily on a patient's baseline gut microbiome. A transition from blind probiotic supplementation to biomarker-guided personalized therapies is advocated.

"Our future research will focus on the use of advanced organ-on-a-chip technology. By cultivating human cells on biomimetic microchips that simulate the gut-liver axis, we can observe the 'cross-kingdom crosstalk' between functional bacteria and host tissues in real-time," said Dr. LIU Yong, the first author of the study.

This study paves the way for highly precise microecological therapies for obesity and metabolic liver diseases.

Figure 1: AKK reshapes hepatic immune and metabolic traits. (Image by LIU Yong)

Figure 2: Pathophysiological progression of MASLD and the stage-dependent therapeutic landscape of AKK. (Image by LIU Yong)